Veniti's Vici Venous Stent to Be Distributed by Boston Scientific


September 11, 2017—Veniti, Inc. announced that Boston Scientific Corporation will distribute the company's Vici venous stent under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved were not disclosed.

The Vici venous stent, which was launched in 2014, is designed to treat iliofemoral venous outflow obstruction. Vici is available in a conventional delivery system, as well as the Vici Verto venous stent system to provide more control in the landing of stents in areas of critical blood flow.

Veniti is currently conducting the VIRTUS trial to evaluate the safety and efficacy of the Vici venous stent for the treatment of chronic iliofemoral venous outflow obstruction under a US Food and Drug Administration investigational device exemption.

The Vici and Vici Verto devices have received CE Mark approval and are commercially available in Europe. The Vici venous stent is approved by the Australian Therapeutic Goods Administration and is commercially available in Australia. In the United States, the devices are limited to investigational use and are not approved for sale, advised Veniti.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.